NL-OMON45541
Completed
Not Applicable
A phase I, open-label, randomized, 4-way crossover study in subjects with chronic Hepatitis B virus infection to assess pharmacokinetics (fasted/fed), safety, tolerability and pharmacodynamics of single oral doses of Farnesoid X receptor agonist EYP001a. - EYP001 study in subjects with chronic hepatitis B virus (HBV) infection
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatitis B
- Sponsor
- ENYO Pharma SA
- Enrollment
- 14
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Has documented chronic HBV infection
- •\- Gender : male or female
- •\- Age : 18\-65 years, inclusive, at screening
- •\- Body mass index (BMI) : 17\.0\-35\.0 kg/m2 inclusive, at screening
Exclusion Criteria
- •Suffering from hepatitis C, cancer or HIV/AIDS. Previous participation in the current study. In case of donating more than 100 milliliters of blood in the 60 days prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A Phase I, open-label, randomized, 2-way crossover trial in 40 healthy subjects to investigate the potential pharmacokinetic interactions between telaprevir and darunavir/ritonavir and between telaprevir and fosamprenavir/ritonavir at steady-statehepatitis C / liver disease10047438NL-OMON32330TIBOTEC PHARMACEUTICALS In Nederland vertegenwoordigd door Janssen-Cilag B.V. afdeling GCO40
Not yet recruiting
Not Applicable
A Phase I, open-label, randomized, 2-way crossover trial in 2 parallel panels of 20 healthy subjects each to investigate the pharmacokinetic interaction between lopinavir/ritonavir (LPV/rtv) and telaprevir, and between atazanavir/ritonavir (ATV/rtv) and telaprevir, all at steady-state.NL-OMON30839Tibotec Pharmaceuticals40
Suspended
Phase 1
To evaluate Safety and Pharmacokinetics of Briogyn (Follitropin alfa, Cadila HealthCare)CTRI/2020/12/029469PSK Pharma LLC
Completed
Not Applicable
A phase 1, open-label, randomized, 2-way crossover study to assess the effects of acid reducing agent(s) on the pharmacokinetics of a single oral dose of JNJ-64417184 in healthy adult participantsNL-OMON50152Janssen-Cilag International NV14
Completed
Phase 4
A phase IV, randomized, open label, cross-over, intervention trial to investigate the effect of the switch of protease inhibitors to raltegravir on endothelial function, chronic inflammation, immune activation and HIV replication below 50 copies/mlNL-OMON39957niversitair Medisch Centrum Utrecht24